COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 604: Articles 6031-6040  | Next

Prevalence and pattern of adverse events following COVID 19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria
Adamu, H., Adamu, A. A., Lawal, S., Bawa, I. A., Sani, A. M.
10.1101/2022.11.01.22281793 — Posted: 2022-11-02
SARS-CoV-2 antibody prevalence among industrial livestock operation workers and nearby community residents, North Carolina, USA, 2021-2022
Gigot, C. M., Pisanic, N., Kruczynski, K., Gregory Rivera, M., Spicer, K., Kurowski, K. M., Randad, P., Koehler, K., Clarke, W., Holmes, P., Hall, D. J., Hall, D., Heaney, C. D.
10.1101/2022.10.31.22281764 — Posted: 2022-11-01
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
Qianqian, L., Jing, C., Kai, S., Ruixin, S., Jiayin, W., Hongmin, L., Yankai, Y., Jing, L., Qing, Y., YanYing, G., Jun, L., Ying, L., Junqing, Y., Chao, Y., Ying, L., Tao, W., Changen, L., Fei, W., Huiling, X.
10.1101/2022.10.30.22281713 — Posted: 2022-11-01
An implementation framework to improve the transparency and reproducibility of computational models of infectious diseases
Pokutnaya, D., Childers, B., Arcury-Quandt, A., Hochheiser, H., Van Panhuis, W. G.
10.1101/2022.10.28.22281671 — Posted: 2022-11-01
Between-Occupation Differences in Work-Related COVID-19 Mitigation Strategies over Time: Analysis of the Virus Watch Cohort in England and Wales
Beale, S., Yavlinsky, A., Hoskins, S. J., Nguyen, V., Byrne, T. E., Fong, W. L. E., Kovar, J., Van Tongeren, M., Aldridge, R. W., Hayward, A.
10.1101/2022.10.31.22281732 — Posted: 2022-11-01
Informed consent and trial prioritization for human subject research during the COVID-19 pandemic. Stakeholder experiences and viewpoints.
Weigold, S., Schorr, S. G., Faust, A., Woydack, L., Strech, D.
10.1101/2022.10.31.22281754 — Posted: 2022-11-01
FULL-SCALE DEEPLY SUPERVISED ATTENTION NETWORK FOR SEGMENTING COVID-19 LESIONS
Dutta, P., Mitra, S.
10.1101/2022.10.26.22281561 — Posted: 2022-11-01
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
Grewal, R., Nguyen, L., Buchan, S. A., Wilson, S. E., Nasreen, S., Austin, P. C., Brown, K. A., Fell, D. B., Gubbay, J., Schwartz, K. L., Tadrous, M., Wilson, K., Kwong, J. C.
10.1101/2022.10.31.22281766 — Posted: 2022-11-01
A cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants
JASSAT, W., Mudara, C., Vika, C., Welch, R., Arendse, T., Dryden, M. T. G., Blumberg, L., Mayet, N., Tempia, S., Parker, A., Nel, J., Perumal, R., Groome, M., Conradie, F., Ndjeka, N., Sigfrid, L., Merson, L., Cohen, C.
10.1101/2022.10.31.22281748 — Posted: 2022-11-01
Phase-wise Impact Analysis of the Indian National Lockdown against COVID-19 Outcomes
Mhasawade, V., Zadey, S., Nair, A.
10.1101/2022.10.27.22281585 — Posted: 2022-11-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).